BioTec CCI AG

Private Investment Firm North Rhine-Westphalia, Germany

Overview

BioTec CCI AG is a German private investment firm focusing on early-stage investments in innovative biotechnology and healthcare companies with high market potential. The firm aims to provide private investors with access to companies that are typically not available to them, leveraging its network to identify promising opportunities. The firm's investment strategy involves co-investments in companies addressing significant needs, particularly those in the early stages of development, such as post-preclinical study phases for drug candidates. These investments are usually in private, non-public companies, offering high value appreciation potential. BioTec CCI AG engages in both direct and indirect investments, including convertible loans, to build a diversified portfolio over the coming years. The team comprises experts with decades of experience in corporate management, capital investment, biotechnology, and medical technology. Notable members include Thomas Ziegelbauer, a financial expert with over 30 years in international corporations, and Hans Hinkel, a sales expert and director at Hinkel & Cie. Vermögensverwaltung AG. The supervisory board includes Michael Schwartzkopff, a lawyer and founding partner of LLR Kanzlei für Wirtschaftsrecht, and Klaus Hinkel, director at Schnigge AG and board member at Hinkel & Cie. Vermögensverwaltung AG. The network partners include Andreas Bergmann, a biochemist with 121 patents and co-founder of several biotech companies, Bernd Wegener, former chairman of the German Association of the Pharmaceutical Industry, and Metod Miklus, board member of the Marjan Miklus Foundation for the Promotion of Science and Research. BioTec CCI AG's portfolio includes investments in PAM Theragnostics GmbH, ADRENOMED AG, 4TEEN4 Pharmaceuticals GmbH, and SphingoTec GmbH. These companies are involved in developing diagnostic tools for diseases related to amidated peptide hormones, with a focus on Alzheimer's disease, and other innovative medical solutions. The firm aims to invest early in companies that make life more livable or even save lives, contributing to advancements in healthcare and medical technology.

Get the full list of 54,000+ investors

BioTec CCI AG and every other firm and angel in the database — as one spreadsheet you keep.

$19one-time payment · no subscription
  • All 54,000+ investors — VC firms, private equity, family offices and angels
  • The key person to contact at each one, with their job title
  • Their work email address
  • Their phone number
  • Their LinkedIn profile
  • Delivered as a single .xlsx file — download it as many times as you like
Get the full list — $19 → One payment. No seats, no credits, no expiry. Already bought it? Sign in to download it again — no second payment.

Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.

Frequently asked questions about BioTec CCI AG

What sectors does BioTec CCI AG invest in?

BioTec CCI AG invests in Healthcare, Biotechnology and Medical Technology, and is based in North Rhine-Westphalia, Germany. BioTec CCI AG is listed as a private investment firm in the ConnectSafely investor database.

What stage does BioTec CCI AG invest at?

BioTec CCI AG backs companies at Seed, Early Stage and Growth, writing cheques of 500K - 5M.

Which regions does BioTec CCI AG invest in?

BioTec CCI AG invests across Germany.

Last updated · Source: ConnectSafely investor database